• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Role of renin-angiotensin system on the promotion of atrial fibrillation.

Research Project

Project/Area Number 11670725
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Circulatory organs internal medicine
Research InstitutionFukuoka University

Principal Investigator

KUMAGAI Koichiro  School of Medicien, Fukuoka University Lecturer, 医学部, 講師 (10248510)

Co-Investigator(Kenkyū-buntansha) URATA Hidenori  School of Medicien, Fukuoka University Lectruer, 医学部, 講師 (30289524)
IDEISHI Munehito  School of Medicine, Fukuoka University Professor, 医学部, 教授 (20131807)
Project Period (FY) 1999 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2001: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2000: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1999: ¥1,100,000 (Direct Cost: ¥1,100,000)
Keywordsatrial fibrillation / remodeling / renin-angiotensin system / angiotensin II receptor antagonist / candesartan / electrophysiology / refractory period / conduction / アンジオテンシン / 心房 / 細動
Research Abstract

Conclusion : Candesartan can prevent the structural remodeling that promotes AF by decreasing the AERP dispersion and conduction delay caused by interstitial fibrosis
Background : We previously reported that an angiotensin II type 1 receptor antagonist, candesartan, prevents acute electrical remodeling in a rapid pacing model. However, the effect of angiotensin II type 1 receptor blockade on chronic structural remodeling in atrial fibrillation (AF) is unclear. Methods and Results : Sustained AF was induced in 20 dogs (10 in a control group and 10 in a candesartan group) by rapid pacing of the right atrium (RA) at 400 bpm for 5 weeks. Candesartan was administered orally (10mg/kg/day) for 1week before rapid pacing, and was continued for 5 weeks. The AF duration, atrial P, effective refractory period (AERP) at 4 sites in the RA and intra-atrial conduction time (CT) from the RA appendage to the other 3 sites were measured every week. The mean AF duration in the control was significantly longer than that with candesartan (1333±725 versus 411±301 sec, p<0.05). The degree of AERP shortening after 5 weeks was not significantly different between the two groups, however, the dispersion of AERP after 5 weeks with candesartan was significantly less than that in the control (20±9 versus 6±3 msec, p<0.05). CT after 5 weeks with candesartan was significantly shorter than that in the control (68±10 versus 43±14 msec, p<0.05). The candesartan group had a significantly lower percentage of interstitial fibrosis than the control group (16±1 versus 7±2%, p<0.05).

Report

(4 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report
  • 1999 Annual Research Report
  • Research Products

    (18 results)

All Other

All Publications (18 results)

  • [Publications] Nakashima H: "Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation"Circulation. 101. 2612-2617 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Kumagai K: "Role of rapid focal activation in the maintenance of atrial fibrillation originating from the pulmonary veins"PACE. 23:[Pt.II]. 1880-1882 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Kumagai K: "Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation : A multicenter trial"PACE. 234:[Pt.II]. 1880-1882 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Gondo N: "Electrophysiological mechanism of combination therapy with disopyramide and propranolol for paroxysmal atrial fibrillation"J Cardiol. 36(6). 405-410 (2000)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Gondo N: "Angiotensin II provokes cesium-induced ventricular tachyarrhythmias"Cardiovascular Research. 49. 381-390 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 熊谷浩一郎: "抗不整脈薬で心筋のリモデリングは防止できるか"心電図. (印刷中).

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Nakashima H, Kumagai K, Urata K, et al.: "Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation"Circulation. 101. 2612-2617 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Kumagai K, Yasuda T, Tojo H, et al.: "Role of rapid focal activation in the maintenance of atrial fibrillation originating from the pulmonary veins"PACE. 23 : [Pt.II]. 1823-1827 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Kumagai K, Abe H, Hiraki T, et al.: "Single oral administration of pilsicaimde versus infusion of disopyramide for termination of paroxysmal atrial fibrillation : A multicenter trial"PACE. 23 : [Pt.II]. 1880-1882 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Gondo N, Kumagai K, Yamanouchi Y, et al.: "lectrophysiological mechanism of combination therapy with disopyramide and propranolol for paroxysmal atrial fibrillation"J Cardiol. 36(6). 405-410 (2000)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Gondo N, Kumagai K, Nakashima H, et al.: "Angiotensin II provokes cesium-induced ventricular tachyarrhythmias"Cardiovascular Research. 49. 381-390 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Kumagai K.: "Can antiarrhythmic agents prevent myocardial remodeling"Japanese J Electrocardiology. (in press).

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Nakashima H: "Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation"Circulation. 101. 2612-2617 (2000)

    • Related Report
      2001 Annual Research Report
  • [Publications] Kumagai K: "Role of rapid focal activation in the maintenance of atrial fibrillation originating from the pulmonary veins"PACE. 23:[Pt.II]. 1823-1827 (2000)

    • Related Report
      2001 Annual Research Report
  • [Publications] Kumagai K: "Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation : A multicenter trial"PACE. 23:[Pt.II]. 1880-1882 (2000)

    • Related Report
      2001 Annual Research Report
  • [Publications] Gondo N: "Electrophysiological mechanism of combination therapy with disopyramide and propranolol for paroxysmal atrial fibrillation"J Cardiol. 36(6). 405-410 (2000)

    • Related Report
      2001 Annual Research Report
  • [Publications] Gondo N: "Angiotensin II provokes cesium-induced ventricular tachyarrhythmias"Cardiovascular Research. 49. 381-390 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 熊谷浩一郎: "抗不整脈薬で心筋のリモデリングは防止できるか"心電図. (印刷中).

    • Related Report
      2001 Annual Research Report

URL: 

Published: 1999-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi